29 results about "Encephalitis Viruses" patented technology

This invention involves, among other things, elements that stimulate an immune response. Which includes: a) one or more antigens of Avibacterium paragallinarum and One or more antigens of avian brain and spinal cord rhizomatous virus and one antigen. or more of avian porcine ... Furthermore, this invention relates to a method for immunizing animals which includes administration. The animal drug contains components that stimulate the immune response of this invention; moreover, This invention relates to a method of treating or preventing clinical signs caused by Avibactericum. Paragallinarum, a viral infection that causes encephalitis and spinal cord inflammation in birds and avian pox virus in animals. Essential, a method that involves administering medication to animals in effective dosages as a form of treatment. The components that stimulate an immune response are consistent with this invention;

The present application relates to the field of biological medicine, in particular to a kind of muscone in the application of viral inhibitor.The viral inhibitor of the present application is used to inhibit the replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus.The present application finds that muscone has no cytotoxicity, and does not directly inactivate virus, but produces antiviral effect on Japanese encephalitis virus by inhibiting NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and other signal pathways, and inhibits porcine epidemic diarrhea virus invasion into cells by reducing caveolin level.The antiviral effect is remarkable, the mechanism of action is clear, the selectivity is high, and the safety is better.

The invention provides a brain organoid / encephalitis B virus infected brain organoid model and a construction method and application thereof, and belongs to the technical field of organoid. The invention provides the kit for constructing the brain organoid, the brain organoid is constructed on the basis of the kit, the construction method of the brain organoid is provided, and the constructed brain organoid model shows clear staged development characteristics, completely reproduces cell diversity in the human brain development process and forms ventricular-like structural characteristics. The encephalitis B virus infected brain organ model constructed on the basis of the obtained brain organs can be used for deeply analyzing the pathogenic process and related immune response characteristics of JEV infected human brain, researching and developing vaccines related to encephalitis B virus and screening antiviral drugs.

The application discloses a recombinant getah virus expressing E protein of Japanese encephalitis virus, the virus has the E protein gene of the Japanese encephalitis virus, and the E protein gene is located between Cap and E3 genes of the genome of the getah virus. A corresponding construction method is also established, the getah virus is used as a parent strain, an infectious clone pGETV-GV thereof is used as a carrier, a truncated E protein of the Japanese encephalitis virus is inserted between Cap and E3 by using a genetic engineering method, and the recombinant getah virus rGECJEV-E is obtained. Tests show that the recombinant getah virus rGECJEV-E has the characteristics of good performance, good stability and high expression amount of exogenous protein, the expressed protein has good immunogenicity, can provide immunoprotection for the attack of the Japanese encephalitis virus, and the safety of the recombinant strain is relatively high. Therefore, the recombinant virus has great potential in preparation of a vaccine or a medicine for preventing or treating the getah virus and / or the Japanese encephalitis virus, and is expected to develop a recombinant bivalent vaccine for the getah virus and the Japanese encephalitis.

The invention belongs to the technical field of virus detection, and particularly relates to a dual-channel real-time fluorescent quantitative PCR (polymerase chain reaction) detection primer, a probe, a detection kit, a detection method and an application of the dual-channel real-time fluorescent quantitative PCR detection primer. Comprising specific primers of the Intity cereal encephalitis virus (Australian encephalitis virus) as shown in SEQ ID NO.1-2 and a probe of the Intity cereal encephalitis virus as shown in SEQ ID NO.3. The detection sensitivity is high, and the lowest detection limit can reach 8 copies / mL; the detection time period is short, nucleic acid detection can be completed within 40 minutes, and the kit is suitable for clinical and bedside rapid detection and diagnosis; the detection specificity is high, and cross amplification with other 80 pathogens is avoided; the detection accuracy is 100%; virus quantitative analysis can be carried out, and the quantitative linear range is good; the detection repeatability is good, and the precision is high.

The disclosure provides a Japanese encephalitis virus transmission risk estimation method and device and electronic equipment, relating to the technical field of disease transmission, the method comprises the steps of: determining a first infection force model, a second infection force model, a first incidence overflow rate model and a second incidence overflow rate model based on mosquito vector data, host infection kinetics data and host data corresponding to a first time interval; estimating the contribution coefficient of vertical transmission basic infection force and mosquito ovitraps index to the infection force of mosquito vector transmission to the host based on the first infection force model and the second infection force model; estimating the intensity coefficient based on the first incidence overflow rate model and the second incidence overflow rate model; estimating the host data of the second time interval based on the vertical transmission basic infection force, the contribution coefficient of the mosquito ovitraps index to the infection force and the intensity coefficient; in this way, the whole chain quantitative evaluation from mosquito vector to host and from host to host can be realized, and the risk evaluation accuracy of host infection virus in a real scene is improved.

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and belongs to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises VH CDR1, VH CDR2 and VH CDR3 of which the amino acid sequences are shown as SEQ ID NO: 1-3, and VL CDR1 and VL CDR3 of which the amino acid sequences are shown as SEQ ID NO: 4 and SEQ ID NO: 5, and the amino acid sequence is VL CDR2 of AAS. The monoclonal antibody LZY2086 provided by the invention can be combined with E protein extracellular regions of the encephalitis B virus and the Zika virus with high affinity, and has very strong neutralizing activity on the encephalitis B virus and the Zika virus. Therefore, as a broad-spectrum neutralizing antibody, the monoclonal antibody LZY2086 disclosed by the invention has ideal clinical application value in prevention and treatment of Japanese encephalitis virus and Zika virus infection.

The application discloses application of a host PRKCSH gene as a target point in prevention and treatment of various RNA virus infections. Experiments prove that knocking out the PRKCSH gene of a pig can significantly inhibit adhesion and invasion of Japanese B encephalitis virus to a host cell, and can also significantly inhibit replication of a classical swine fever virus, a porcine transmissible gastroenteritis virus, a Senecavirus, a porcine epidemic diarrhea virus and a porcine reproductive and respiratory syndrome virus in the host cell. In addition, knocking out the PRKCSH gene of a human can significantly inhibit replication of the Japanese B encephalitis virus in the host cell. Therefore, specific targeted editing of the PRKCSH gene or interference with protein expression of the PRKCSH gene can inhibit infection of various RNA viruses to host cells.

The invention discloses application of KML29 in preparation of a medicine for inhibiting Japanese encephalitis virus infection, discovers that KML29 can significantly inhibit Japanese encephalitis virus replication, and discovers that KML29 not only inhibits transcription of Japanese encephalitis virus, but also can reduce expression of NS5 protein. Therefore, the KML29 can be used for preventing or treating the Japanese encephalitis virus.

The invention belongs to the field of development of antiviral drugs, and particularly relates to application of LEI-401 in preparation of drugs for resisting epidemic encephalitis B virus infection. The CAS number of the LEI-401 is 2393840-15-6, the invention discloses that the LEI-401 can obviously inhibit Japanese encephalitis virus replication and reduce virus load for the first time, and proves that the LEI-401 can improve the survival rate of infected mice, has good antiviral activity and safety in an animal model, and can be used for developing drugs for treating or preventing epidemic Japanese encephalitis virus infection. The invention also provides a suspension for resisting epidemic encephalitis B virus infection. The suspension has the advantages of safety, high efficiency and wide application prospect.

The application provides application of embelin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the embelin has significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.

This invention discloses labeled antibodies and related biological materials, and their application in the detection of tick-borne encephalitis virus (TEV). The application includes any of the following: (1) preparing products for detecting TEV; (2) preparing products binding to the TEV E protein; (3) detecting TEV; and (4) binding to the TEV E protein. Compared with traditional HRP-labeled antibodies, this labeled antibody has higher detection sensitivity.

The invention provides a tick-borne encephalitis virus monoclonal antibody and application thereof, and relates to the field of biotechnology and virology. A mouse monoclonal antibody mAb-16 with specific neutralizing activity is screened, the monoclonal antibody mAb-16 mainly aims at envelope protein E of tick-borne encephalitis virus, the monoclonal antibody mAb-16 can specifically recognize and neutralize domain III in E protein EDIII of tick-borne encephalitis virus, and a biological membrane layer interference experiment shows that the monoclonal antibody mAb-16 has relatively strong interaction with the domain III of the E protein. The median inhibition concentration of the monoclonal antibody mAb-16 on primary viruses cultured by sensitive cells is 92.80 ng / mL; in a lethal mouse infection model, a high-dose group has complete protection activity and can be used for preparing tick-borne encephalitis virus detection reagents or related drugs for neutralizing and inhibiting tick-borne encephalitis viruses, so that prevention and treatment of tick-borne encephalitis viruses are facilitated.

The first aspect of the invention relates to the amino acid sequence of the recombinant virus-like particles (VLPs) shown as the sequence number SEQ 1, based on the natural TBEV proteins: the prM and E protein. The change in the sequence of natural proteins refers, inter alia, to the introduction of additional modified sequences into the sequence of natural proteins, i.e., the signal sequence for LMSAP1 phosphatase from Leishmania mexicana, e.g., the signal sequence from the LEXSinduce3 Expression Kit expression system and P2A sequence, which result in more efficient overproduction of VLPs and increase their immunogenicity. A second aspect of the invention relates to recombinant VLPs with the amino acid sequence according to the invention (SEQ 1) for medical use in the prevention and control of tick-borne encephalitis, especially when used in a form of a vaccine component.

The invention discloses a vaccine for preventing and treating swine Japanese encephalitis virus and application, and belongs to the field of biological pharmacy for livestock. The CHO stable expression cell line expressing the E protein Domain III is constructed, transcription and protein expression levels are remarkably improved, the cell line grows under the glutamine-free condition, accumulation of metabolites such as ammonia is reduced, and cell activity and long-term culture stability are improved. The FC fusion protein is added after the ED3 gene sequence through the flexible Linker, so that the affinity chromatography purification process is simplified, the recovery rate and the purity are improved, and the production cost is reduced; meanwhile, the high-efficiency expression of CHO cells is combined, so that the purified protein yield is higher than 2g / L, which is far better than that of a traditional method, and the large-scale requirement of veterinary vaccines is met. The vaccine provided by the invention has no pathogen residual risk, the safety is higher than that of the traditional inactivated or attenuated live vaccine, and the vaccine which is safe, reliable and good in immunogenicity is provided for preventing and treating infection of the swine Japanese encephalitis virus.

The invention discloses an ELISA detection kit for detecting forest encephalitis virus envelope E protein, and relates to the technical field of kits. The kit comprises a pre-coated elisa plate, an elisa antibody, a TBEV E protein quantitative standard substance, a sample diluent, a 20-time concentrated washing solution, a chromogenic substrate A, a chromogenic substrate B, a stop buffer, a plate sealing film and a drying agent. According to the present invention, the totivirus specific correlation can be identified, and the method can be used for the preparation of the kit quality control product so as to achieve the quantitative detection, and is suitable for the E protein preparation and the identification of the specific virus protein monoclonal antibody.

The invention provides a Japanese encephalitis virus transmission risk estimation method and device and electronic equipment, and relates to the technical field of disease transmission, and the method comprises the steps: storing main infection dynamics data and host data based on mosquito-borne data corresponding to a first time interval, determining a first infection model, a second infection model, a first disease overflow rate model and a second disease overflow rate model; estimating the contribution coefficient of the vertical propagation basic infectivity and the mosquito-borne egg trap index to the infectivity of mosquito-borne propagation to the main storage body based on the first infectivity model and the second infectivity model; estimating an intensity coefficient based on the first disease overflow rate model and the second disease overflow rate model; estimating host data in a second time interval based on the vertical propagation basic infectivity, the contribution coefficient of the mosquito-borne egg trap index to the infectivity and the strength coefficient; therefore, full-chain quantitative evaluation from mosquito vector to storage host and from storage host to host can be realized, and the risk evaluation precision of host virus infection in a real scene is improved.

The application belongs to the technical field of biological medicine, and provides a tick-borne encephalitis virus vaccine based on bacterial-like particles, a preparation method and application thereof, wherein the tick-borne encephalitis virus vaccine is EDc2&MAB2560-GEM co-display bacterial-like particles, which are prepared by co-displaying recombinant antigen protein TBEV E-DIII-Dcpep2-PA3 and recombinant adjuvant protein MAB2560-PA3 on the surface of GEM particles; the prepared tick-borne encephalitis virus vaccine has good immunogenicity and can induce animals to produce efficient and persistent specific immune responses.

The invention relates to the field of biological detection, in particular to a primer probe set, a detection reagent and application of the primer probe set and the detection reagent in detection of virulent pathogens. The invention provides a primer probe group. Comprising the following steps: amplifying lasa fever virus, Xinjiang hemorrhagic fever virus, Zaire Ebola virus, Chikungunya virus, monkey pox virus, eastern equine encephalitis virus and tick-borne encephalitis virus; and the primer probe group is used for amplifying the Venezuela equine encephalitis virus and the Rift Valley fever virus. The kit is in a freeze-dried solid state and can be transported and stored at normal temperature. The kit is good in sample compatibility, the matched sample lysate can directly expand the sample, nucleic acid purification is not needed, nine virulent pathogens can be simultaneously detected in a one-tube reaction system, rapid screening of large-batch samples is achieved, the whole-process detection is within 1 h, and the result is accurate and reliable.

According to the invention, a Chinese forest encephalitis virus inactivated vaccine is adopted to produce a strain'senzheng 'strain gene sequence, a structural protein preM-E gene sequence of the strain is amplified, an HIV-1 lentivirus packaging system is utilized, preM-E is used as a pseudovirus particle envelope protein, green fluorescent protein (EGFP) or luciferase reporter gene (Luciferae) is used as a detection indication signal to prepare the pseudovirus, and a BHK21 cell is used as a target cell; the pseudovirus-BHK21 cell system is used for replacing live virus operation experiments such as vaccine potency evaluation, neutralizing antibody detection (animal method or plaque reduction neutralization test) and the like, the biosafety operation environment is degraded from BSL-3 to BSL-2 by using pseudoviruses, the detection period is shortened, and animal experiments are reduced.

This application provides a multiplex quantitative PCR detection kit for mosquito-borne viruses and its detection method. The detection kit includes a multiplex PCR reaction solution, a positive control, and a negative control. The multiplex PCR reaction solution includes four specific probes and four pairs of specific primers for detecting dengue virus, Japanese encephalitis virus, Zika virus, and West Nile virus, respectively. The detection method includes sample extraction, preparation of the PCR mixture of reagents, PCR amplification, and fluorescence signal reading. Through the above methods, this application can specifically identify dengue virus, Japanese encephalitis virus, Zika virus, and West Nile virus. By combining a standard curve, it can quantitatively detect dengue virus, Japanese encephalitis virus, Zika virus, and West Nile virus, with high detection efficiency, stable implementation, simple and rapid operation, high detection speed, and high detection accuracy and sensitivity.

The present disclosure provides novel broadly neutralizing anti-tick-borne encephalitis virus (TBEV) antibodies. Anti-TBEV antibodies are induced by various tick-borne flaviviruses, including TBEV. These represent novel therapeutic strategies for preventing or treating the associated diseases or infections.

This invention belongs to the field of genetic engineering technology, specifically relating to a method for constructing a porcine ATP6v0d2 (sATP6v0d2) knockout PK15 cell line and its application in inhibiting Japanese encephalitis virus infection. This invention provides a specific sgRNA targeting sATP6v0d2, and combined with CRI SPR / Cas9 gene editing technology, achieves sATP6v0d2 gene knockout in porcine kidney PK15 cells. The resulting monoclonal cells significantly inhibit Japanese encephalitis virus infection, which is of great significance for the prevention and treatment of Japanese encephalitis. This method is simple and efficient, and the constructed cell line can be widely used in research related to ATP6v0d2 gene function and Japanese encephalitis virus infection, showing broad application prospects.

This invention discloses a method for screening drugs against Japanese encephalitis virus, which uses the main protease NS3 of Japanese encephalitis virus. pro The activity reporter plasmid and the main protease NS3 of Japanese encephalitis virus pro Expression plasmids were used to screen for drugs against Japanese encephalitis virus; NS3 pro Active reporter plasmids and NS3 pro The expression plasmid was co-transfected into HEK-293T cells. The fluorescence intensity of green fluorescent protein (EGFP) was detected using an inverted fluorescence microscope and a multi-functional microplate reader to predict NS3. pro The activity of NS3, the main protease of JEV, can be used to screen for its activity. pro The purpose of this invention is to screen anti-JEV compounds using active reporter plasmids. The inhibitory effect of the compounds can be observed more intuitively and easily by utilizing fluorescence intensity, providing a powerful tool for screening broad-spectrum anti-JEV compounds.

The invention discloses an application of a marketed drug AZD-9291 (Osimertinib, osimertinib) in resisting infection of alphaviruses such as ONNV (O'nyong-nyong virus) and the like, and relates to the technical field of drugs, in particular to an application of the drug AZD-9291 (Osimertinib, osimertinib) in resisting infection of alphaviruses such as ONNV (O'nyong-nyong virus) and the like. Experimental results show that the AZD-9291 can be used for effectively inhibiting the infection of four pseudovirus particles, namely ONNV (ONNV), CHIKV (Chikungunya virus), EEEV (Eastern equine encephalitis virus) and SFV (Semliki Forest Virus), on host cells, and the AZD-9291 can be used for effectively inhibiting the infection of the four pseudovirus particles, namely ONNV, CHIKV, Chikungunya virus, EEEV, Eastern equine encephalitis virus, and SFV (Semliki Forest Virus, forest encephalitis virus). The CC50 of AZD-9291 in HEK293T cells is determined to be 53.3 [mu] M, then the inhibition effect of the compound on ONNV pseudoviruses is determined, the IC50 of the compound is 1.41 [mu] M, and meanwhile, the compound is found to have no inhibition effect on infection of rVSV [delta] G-G control pseudoviruses. Subsequently, the inhibition effect of AZD-9291 on other alphaviruses such as CHIKV, EEEV and SFV in HEK293T cells is determined, and the IC50 (half maximal inhibitory concentration) of AZD-9291 is 3.74 mu M, 5.18 mu M and 3.47 mu M respectively. The research proves that AZD-9291 can be used as a broad-spectrum candidate drug for inhibiting infection of alphaviruses such as ONNV, CHIKV and the like, and new application and new prospect of AZD-9291 as a clinical alphavirus infection treatment drug and preparation are shown.

The application provides application of hypericin in preparation of a medicine for resisting St. Louis encephalitis virus infection. The application has the beneficial effect that the hypericin has a significant inhibitory effect on NS2B-NS3 protease activity in the St. Louis encephalitis virus, can be used as an inhibitor of the NS2B-NS3 protease in the St. Louis encephalitis virus, and is expected to become a potential medicine for resisting St. Louis encephalitis virus infection.

The application discloses a porcine Gertvirus and porcine encephalitis virus B double gene engineering subunit vaccine and a preparation method and application thereof. The core components of the vaccine are Gertvirus P6E recombinant protein and encephalitis virus B DFN fusion protein, and a recombinant nanoparticle loaded with the antigens. The obtained recombinant protein or recombinant nanoparticle is compounded with an adjuvant to prepare the GETV / JEV double gene engineering vaccine, and the GETV / JEV double gene engineering vaccine can induce strong humoral and cellular immune responses of a host after two immunizations, and effectively protects the body from GETV and JEV infection. The technical scheme of the application provides important reference and technical support for developing the GETV / JEV double vaccine with high safety, high immunogenicity and suitable for large-scale production.

The invention discloses a porcine getavirus and porcine Japanese encephalitis virus bivalent genetic engineering subunit vaccine as well as a preparation method and application thereof. The core components of the vaccine comprise a Getah virus P6E recombinant protein and a Japanese encephalitis virus DFN fusion protein, and recombinant nanoparticles loaded with the antigens. The obtained recombinant protein or recombinant nanoparticles are compounded with an adjuvant to prepare the GETV / JEV bigeminy genetic engineering vaccine, a host can be induced to generate strong humoral immune and cellular immune response through two times of immunization, and a body is effectively protected from being infected by GETV and JEV. According to the technical scheme, important reference and technical support are provided for developing the GETV / JEV bivalent vaccine which has high safety and high immunogenicity and is suitable for large-scale production.